Hervé Brailly, CEO, is invited to the panel discussion "French Public Markets – Breakthrough Technologies Panel".
Zurich,Switzerland
More info
News & events
Innate pharma reports higher annual revenue in 2011
February 7, 2012
- Revenue of 11.7 million euros including payments from partners Bristol-Myers Squibb and Novo Nordisk A/S as well as research tax credit
- Strong cash position with 46.6 million euros in cash, cash equivalents and current financial instruments as at December 31, 2011
(IFRS unaudited provisional data)
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces revenue and other income of 11.7 million euros for the year 2011, compared to 4.3 million euros in 2010.
Novel immune regulation mechanism involving Natural Killer Cells described and published in "Science" magazine by a key academic partner of Innate Pharma
January 20, 2012
- Innate Pharma co-owns intellectual property rights relating to the NKp46 receptor with INSERM, the French National Institute of Health and Medical Research
- Endorses Innate Pharma’s fruitful collaboration with leading academics on Natural Killer cell science
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, is pleased to note today that an important discovery in the field of innate immunity, made by a team led by Professor Eric Vivier, Innate Pharma’s scientific co-founder at the Center of Immunology of Marseille-Luminy (CIML), has been published in the prestigious journal Science.
Half-year report on Innate Pharma's liquidity contract with Natixis Securities
January 2, 2012
Under the liquidity contract entrusted by INNATE PHARMA to NATIXIS SECURITIES, the following assets appeared on the liquidity account as at December 31, 2011:
- 155,175 shares of INNATE PHARMA, and
- 34,986.66 euros in cash.
Innate Pharma announces its financial calendar for 2012 as well as its participations to upcoming investor conferences
December 21, 2011
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today its tentative financial calendar for 2012.
Innate Pharma SA announces its participation in Actionaria on November 18 & 19 in Paris
November 4, 2011
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces its participation in Actionaria, a forum dedicated to meeting with individual investors, on November 18 & 19, in Paris.
- Innate Pharma will present the Company and answer your questions at its stand (A16, level 1).
- Hervé Brailly, Chief Executive Officer, will be at the “Agora of Presidents” on Friday, November 18 at 11:25 am.
Innate Pharma announces its turnover for the first nine months of 2011 and updates on its cash position
November 4, 2011
Turnover of 3.1 million euros
Cash position as at September 30, 2011 of 49.3 million euros
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces a turnover of 3.1 million euros for the first nine months of 2011, compared with 0.2 million euros for the same period in 2010.